Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [18F]DOPA PET Study.

Kim E, Howes OD, Veronese M, Beck K, Seo S, Park JW, Lee JS, Lee YS, Kwon JS.

Neuropsychopharmacology. 2017 Mar;42(4):941-950. doi: 10.1038/npp.2016.258. Epub 2016 Nov 18.

PMID:
27857125
2.

Role of purinergic P2X4 receptors in regulating striatal dopamine homeostasis and dependent behaviors.

Khoja S, Shah V, Garcia D, Asatryan L, Jakowec MW, Davies DL.

J Neurochem. 2016 Oct;139(1):134-48. doi: 10.1111/jnc.13734. Epub 2016 Aug 15.

PMID:
27402173
3.

Pathway-Specific Dopamine Abnormalities in Schizophrenia.

Weinstein JJ, Chohan MO, Slifstein M, Kegeles LS, Moore H, Abi-Dargham A.

Biol Psychiatry. 2017 Jan 1;81(1):31-42. doi: 10.1016/j.biopsych.2016.03.2104. Epub 2016 Mar 31. Review.

PMID:
27206569
4.

Effects of prenatal exposure to different colors on offsprings mood.

Faryadian S, Khosravi A.

Iran J Basic Med Sci. 2015 Nov;18(11):1086-92.

5.

Eliminating the Attentional Blink through Binaural Beats: A Case for Tailored Cognitive Enhancement.

Reedijk SA, Bolders A, Colzato LS, Hommel B.

Front Psychiatry. 2015 Jun 4;6:82. doi: 10.3389/fpsyt.2015.00082. eCollection 2015.

6.

Asymmetry of Dopamine D2/3 Receptor Availability in Dorsal Putamen and Body Mass Index in Non-obese Healthy Males.

Cho SS, Yoon EJ, Kim SE.

Exp Neurobiol. 2015 Mar;24(1):90-4. doi: 10.5607/en.2015.24.1.90. Epub 2015 Jan 21.

7.

Neuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia.

Nakajima S, Takeuchi H, Plitman E, Fervaha G, Gerretsen P, Caravaggio F, Chung JK, Iwata Y, Remington G, Graff-Guerrero A.

Schizophr Res. 2015 May;164(1-3):164-75. doi: 10.1016/j.schres.2015.01.043. Epub 2015 Feb 13. Review.

8.

Ventral striatal dopamine reflects behavioral and neural signatures of model-based control during sequential decision making.

Deserno L, Huys QJ, Boehme R, Buchert R, Heinze HJ, Grace AA, Dolan RJ, Heinz A, Schlagenhauf F.

Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):1595-600. doi: 10.1073/pnas.1417219112. Epub 2015 Jan 20.

9.

Glutamate and dopamine in schizophrenia: an update for the 21st century.

Howes O, McCutcheon R, Stone J.

J Psychopharmacol. 2015 Feb;29(2):97-115. doi: 10.1177/0269881114563634. Epub 2015 Jan 13. Review.

10.

The neurobiology and treatment of first-episode schizophrenia.

Kahn RS, Sommer IE.

Mol Psychiatry. 2015 Feb;20(1):84-97. doi: 10.1038/mp.2014.66. Epub 2014 Jul 22. Review.

11.

Hemispheric differences in the mesostriatal dopaminergic system.

Molochnikov I, Cohen D.

Front Syst Neurosci. 2014 Jun 11;8:110. doi: 10.3389/fnsys.2014.00110. eCollection 2014. Review.

12.

Dopamine function in cigarette smokers: an [¹⁸F]-DOPA PET study.

Bloomfield MA, Pepper F, Egerton A, Demjaha A, Tomasi G, Mouchlianitis E, Maximen L, Veronese M, Turkheimer F, Selvaraj S, Howes OD.

Neuropsychopharmacology. 2014 Sep;39(10):2397-404. doi: 10.1038/npp.2014.87. Epub 2014 Apr 10.

13.

Ventral striatum gray matter density reduction in patients with schizophrenia and psychotic emotional dysregulation.

Stegmayer K, Horn H, Federspiel A, Razavi N, Bracht T, Laimböck K, Strik W, Dierks T, Wiest R, Müller TJ, Walther S.

Neuroimage Clin. 2013 Dec 27;4:232-9. doi: 10.1016/j.nicl.2013.12.007. eCollection 2014.

14.

Love to win or hate to Lose? Asymmetry of dopamine D2 receptor binding predicts sensitivity to reward versus punishment.

Tomer R, Slagter HA, Christian BT, Fox AS, King CR, Murali D, Gluck MA, Davidson RJ.

J Cogn Neurosci. 2014 May;26(5):1039-48. doi: 10.1162/jocn_a_00544. Epub 2013 Dec 17.

15.

Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging study.

Howes OD, Williams M, Ibrahim K, Leung G, Egerton A, McGuire PK, Turkheimer F.

Brain. 2013 Nov;136(Pt 11):3242-51. doi: 10.1093/brain/awt264. Epub 2013 Oct 3.

16.

Biomarker investigations related to pathophysiological pathways in schizophrenia and psychosis.

Chana G, Bousman CA, Money TT, Gibbons A, Gillett P, Dean B, Everall IP.

Front Cell Neurosci. 2013 Jun 26;7:95. doi: 10.3389/fncel.2013.00095. eCollection 2013.

17.

Abnormal striatal dopamine transmission in schizophrenia.

Brunelin J, Fecteau S, Suaud-Chagny MF.

Curr Med Chem. 2013;20(3):397-404. Review.

18.

Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [(18)F/(11)C]-DOPA PET studies.

Fusar-Poli P, Meyer-Lindenberg A.

Schizophr Bull. 2013 Jan;39(1):33-42. doi: 10.1093/schbul/sbr180. Epub 2012 Jan 26.

19.

Dopamine in the history of the schizophrenic brain: recent contributions of brain-imaging studies.

Lamelle M, Abi-Dargham A.

Dialogues Clin Neurosci. 2000 Dec;2(4):359-72.

20.

Abnormal relationship between medial temporal lobe and subcortical dopamine function in people with an ultra high risk for psychosis.

Allen P, Chaddock CA, Howes OD, Egerton A, Seal ML, Fusar-Poli P, Valli I, Day F, McGuire PK.

Schizophr Bull. 2012 Sep;38(5):1040-9. doi: 10.1093/schbul/sbr017. Epub 2011 May 2.

Supplemental Content

Support Center